Immuneering (NASDAQ:IMRX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Immuneering (NASDAQ:IMRX) issued its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.09, FiscalAI reports.

Immuneering Price Performance

Immuneering stock opened at $5.16 on Friday. The company’s 50 day simple moving average is $5.35 and its 200 day simple moving average is $5.70. Immuneering has a fifty-two week low of $1.29 and a fifty-two week high of $10.08. The firm has a market capitalization of $333.84 million, a price-to-earnings ratio of -3.74 and a beta of 0.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMRX. Jane Street Group LLC bought a new position in Immuneering during the 1st quarter worth approximately $32,000. Geode Capital Management LLC boosted its stake in Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after acquiring an additional 4,458 shares during the last quarter. XTX Topco Ltd bought a new position in Immuneering in the second quarter valued at approximately $90,000. Bridgeway Capital Management LLC lifted its stake in Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after buying an additional 35,000 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Immuneering in the second quarter valued at approximately $215,000. Institutional investors own 67.65% of the company’s stock.

Wall Street Analyst Weigh In

IMRX has been the subject of several analyst reports. Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.